341 related articles for article (PubMed ID: 30115959)
1. Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies.
Alpajaro SIR; Harris JAK; Evans CP
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):16-23. PubMed ID: 30115959
[TBL] [Abstract][Full Text] [Related]
2. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086
[TBL] [Abstract][Full Text] [Related]
3. M0CRPC overview of management options.
Hess-Busch Y; Hadaschik B; Hess J
World J Urol; 2021 Feb; 39(2):349-356. PubMed ID: 31691081
[TBL] [Abstract][Full Text] [Related]
4. Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.
Swami U; Agarwal N
Cancer Treat Res Commun; 2020; 25():100205. PubMed ID: 32822968
[TBL] [Abstract][Full Text] [Related]
5. [Non-metastatic castration-resistant prostate cancer (M0CRPC) - Apalutamide in high-risk M0CRPC: case reports from the SPARTAN study and the apalutamide compassionate use program].
Spiegelhalder P; Bögemann M
Aktuelle Urol; 2022 Feb; 53(1):60-63. PubMed ID: 33882583
[TBL] [Abstract][Full Text] [Related]
6. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S
Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
[TBL] [Abstract][Full Text] [Related]
7. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
Chowdhury S; Oudard S; Uemura H; Joniau S; Dearden L; Capone C; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2022 Jan; 39(1):518-531. PubMed ID: 34797506
[TBL] [Abstract][Full Text] [Related]
8. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
Fizazi K; Smith MR; Tombal B
Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of nonmetastatic CRPC : Androgen receptor inhibition as new treatment standard in nonmetastatic castration-resistant prostate cancer with high risk of metastasis].
Hadaschik B; Hellmis E
Urologe A; 2021 Jun; 60(6):753-759. PubMed ID: 33575824
[TBL] [Abstract][Full Text] [Related]
10. [Apalutamide in patients with high-risk M0CRPC: data from the pivotal SPARTAN study and initial experience from a compassionate use program].
Hellmis E; Schwentner C; Mandel P; Banek S; Gleißner J; Bögemann M
Aktuelle Urol; 2023 Apr; 54(2):140-147. PubMed ID: 33621992
[TBL] [Abstract][Full Text] [Related]
11. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
12. Treatment and trials in non-metastatic castration-resistant prostate cancer.
Lokeshwar SD; Klaassen Z; Saad F
Nat Rev Urol; 2021 Jul; 18(7):433-442. PubMed ID: 34002069
[TBL] [Abstract][Full Text] [Related]
13. Non-metastatic castration-resistant prostate cancer: current status and future directions.
Gupta R; Sheng IY; Barata PC; Garcia JA
Expert Rev Anticancer Ther; 2020 Jun; 20(6):513-522. PubMed ID: 32508166
[TBL] [Abstract][Full Text] [Related]
14. Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
Al-Salama ZT
Drugs; 2019 Sep; 79(14):1591-1598. PubMed ID: 31489589
[TBL] [Abstract][Full Text] [Related]
15. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW
Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354
[TBL] [Abstract][Full Text] [Related]
16. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
Saad F; Small EJ; Feng FY; Graff JN; Olmos D; Hadaschik BA; Oudard S; Londhe A; Bhaumik A; Lopez-Gitlitz A; Thomas S; Mundle SD; Chowdhury S; Smith MR
Eur Urol; 2022 Feb; 81(2):184-192. PubMed ID: 34916086
[TBL] [Abstract][Full Text] [Related]
17. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
Feng FY; Thomas S; Saad F; Gormley M; Yu MK; Ricci DS; Rooney B; Brookman-May S; McCarthy S; Olmos D; Chowdhury S; Hadaschik B; Liu Y; Davicioni E; Smith MR; Small EJ
JAMA Oncol; 2021 Jul; 7(7):1005-1014. PubMed ID: 34081076
[TBL] [Abstract][Full Text] [Related]
18. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
19. Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide.
Gul A; Garcia JA; Barata PC
Cancer Manag Res; 2019; 11():7253-7262. PubMed ID: 31534371
[TBL] [Abstract][Full Text] [Related]
20. Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
Smith MR; Thomas S; Gormley M; Chowdhury S; Olmos D; Oudard S; Feng FY; Rajpurohit Y; Urtishak K; Ricci DS; Rooney B; Lopez-Gitlitz A; Yu M; Wyatt AW; Li M; Attard G; Small EJ
Clin Cancer Res; 2021 Aug; 27(16):4539-4548. PubMed ID: 34112710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]